| Literature DB >> 33256696 |
Sheela B Abraham1,2, Farah Al Marzooq3, Wan Harun Himratul-Aznita4, Hany Mohamed Aly Ahmed2, Lakshman Perera Samaranayake5,6.
Abstract
BACKGROUND: There is limited data on the prevalence of Candida species in infected root canal systems of human teeth. We attempted to investigate the prevalence, genotype, virulence and the antifungal susceptibility of Candida albicans isolated from infected root canals of patients with primary and post-treatment infections in a UAE population.Entities:
Keywords: Antifungals; Biofilm formation; Candida albicans; Haemolysin; Phospholipase; Root canal infection; Virulence
Year: 2020 PMID: 33256696 PMCID: PMC7708210 DOI: 10.1186/s12903-020-01347-5
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Amplicon sizes (base pairs) results from Multiplex PCR amplification using yeast specific (Universal-UNI1 and UNI2) and corresponding species-specific primers of Candida species
| Species | Primer | Sequence (5′-3′) | Amplicon size (bp) |
|---|---|---|---|
| UNI 1 | |||
| UNI 2 | |||
| Calb | AGCTGCCGCCAGAGGTCTAA | 583/446 | |
| Ctro | GATTTGCTTAATTGCCCCAC | 583/507 | |
| Ckru | CTGGCCGAGCGAACTAGACT | 590/169 | |
| Cgla | TTGTCTGAGCTCGGAGAGAG | 929/839 | |
| Cdub | CTCAAACCCCTAGGGTTTGG | 591/217 | |
| Cpar | GTCAACCGATTATTTAATAG | 570/370 |
Fig. 1Agarose gel electrophoresis for the ABC typing of test and reference strains. †Upper row: Lane 1-U1, 2-U2, 3-U3, 4-U4, 5-F1, 6-F2, 7-F3, 8-F4, 9-100 bp DNA ladder. Bottom row: Lane 10-S1, 11-S2, 12-S3, 13-S4, 14-C. parapsilosis (ATCC 22019), 15-C. albicans (ATCC 90028), 16–100 bp DNA Ladder. ‡Note- UAE strains-U1, U2, U3 U4 Finland strains-F1, F2, F3, F4 Salivary strains-S1, S2, S3, S4
Comparison of virulence properties between the UAE strains, Finland strains and the saliva strains with reference strains; C. albicans (ATCC90028) and C. parapsilosis (ATCC 22019)
| Strain | N | CV assay | XTT assay | Phospholipase | Haemolysin | ||||
|---|---|---|---|---|---|---|---|---|---|
ATCC 90028 | 1 | 3.67(0.25) | 1.43(0.34) | 0.46(0.06) | 0.51(0.02) | ||||
ATCC 22019 | 1 | ND | ND | 1.00 | 1.00 | ||||
UAEa,b | 4 | 2.69 (1.38) | 0.69 NS | 1.07(0.71) | 0.74 NS | 0.46(0.08) | 0.035c | 0.53(0.13) | 0.023c |
Finlanda | 4 | 2.94 (1.03) | 0.81 (0.51) | 0.64 (0.10) | 0.56(0.01) | ||||
Salivab | 4 | 2.29 (0.50) | 0.83 (0.18) | 0.61(0.07) | 0.49(0.04) |
a,cSignificant at p < 0.05 (ANOVA) for phospholipase
b,cSignificant at p < 0.05 (ANOVA) for haemolysin
N, number of strains; ND, not done; NS, not significant
Comparison of antifungal susceptibility between the UAE strains, Finland strains and the saliva strains with reference strains C. albicans (ATCC90028) and C. parapsilosis (ATCC 22019)
| Strain | N | Amphotericin B | Fluoconazole | Ketoconazole | Nystatin | ||||
|---|---|---|---|---|---|---|---|---|---|
ATCC 90028 | 1 | 1.04 (0.36) | 0.62 (0.00) | 2.50 (0.00) | 1.66 (0.72) | ||||
ATCC 22019 | 1 | 0.41 (0.18) | 1.67 (0.72) | 0.26 (0.09) | 0.62 (0.00) | ||||
UAEa | 4 | 1.09 (0.46) | 0.051 NS | 0.62 (0.17) | 0.036b | 1.41 (1.04) | 0.947 NS | 1.25 (0.33) | 0.213 NS |
Finland | 4 | 0.55 (0.10) | 0.42 (0.15) | 1.41 (0.79) | 1.72 (0.59) | ||||
Salivaa | 4 | 0.65 (0.13) | 0.34(0.05) | 1.25 (0.34) | 1.14 (0.36) |
a,bSignificant at p < 0.05 (ANOVA) for Fluoconazole
N, number of strains; NS, not significant